Logo image of CSTE

CAESARSTONE LTD (CSTE) Stock Fundamental Analysis

NASDAQ:CSTE - Nasdaq - IL0011259137 - Common Stock - Currency: USD

1.75  +0.03 (+1.74%)

Fundamental Rating

2

Overall CSTE gets a fundamental rating of 2 out of 10. We evaluated CSTE against 42 industry peers in the Building Products industry. CSTE scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. CSTE does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CSTE had negative earnings in the past year.
In the past year CSTE had a positive cash flow from operations.
In multiple years CSTE reported negative net income over the last 5 years.
Of the past 5 years CSTE 4 years had a positive operating cash flow.
CSTE Yearly Net Income VS EBIT VS OCF VS FCFCSTE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M -100M

1.2 Ratios

CSTE has a worse Return On Assets (-8.68%) than 83.33% of its industry peers.
CSTE's Return On Equity of -17.69% is on the low side compared to the rest of the industry. CSTE is outperformed by 80.95% of its industry peers.
Industry RankSector Rank
ROA -8.68%
ROE -17.69%
ROIC N/A
ROA(3y)-11.12%
ROA(5y)-6.06%
ROE(3y)-20.4%
ROE(5y)-11.19%
ROIC(3y)N/A
ROIC(5y)N/A
CSTE Yearly ROA, ROE, ROICCSTE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20 -30

1.3 Margins

With a Gross Margin value of 20.93%, CSTE is not doing good in the industry: 76.19% of the companies in the same industry are doing better.
CSTE's Gross Margin has declined in the last couple of years.
CSTE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 20.93%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.44%
GM growth 5Y-4.33%
CSTE Yearly Profit, Operating, Gross MarginsCSTE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 30 40

More info and screens

4

2. Health

2.1 Basic Checks

CSTE does not have a ROIC to compare to the WACC, probably because it is not profitable.
CSTE has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, CSTE has more shares outstanding
The debt/assets ratio for CSTE has been reduced compared to a year ago.
CSTE Yearly Shares OutstandingCSTE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
CSTE Yearly Total Debt VS Total AssetsCSTE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

CSTE has an Altman-Z score of 1.48. This is a bad value and indicates that CSTE is not financially healthy and even has some risk of bankruptcy.
CSTE's Altman-Z score of 1.48 is on the low side compared to the rest of the industry. CSTE is outperformed by 90.48% of its industry peers.
CSTE has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.00, CSTE belongs to the top of the industry, outperforming 85.71% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.48
ROIC/WACCN/A
WACC8.78%
CSTE Yearly LT Debt VS Equity VS FCFCSTE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

A Current Ratio of 2.22 indicates that CSTE has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 2.22, CSTE is in line with its industry, outperforming 59.52% of the companies in the same industry.
CSTE has a Quick Ratio of 1.46. This is a normal value and indicates that CSTE is financially healthy and should not expect problems in meeting its short term obligations.
CSTE has a Quick ratio (1.46) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 2.22
Quick Ratio 1.46
CSTE Yearly Current Assets VS Current LiabilitesCSTE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

2

3. Growth

3.1 Past

CSTE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.54%, which is quite impressive.
The Revenue for CSTE has decreased by -20.35% in the past year. This is quite bad
The Revenue has been decreasing by -4.09% on average over the past years.
EPS 1Y (TTM)21.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-123.08%
Revenue 1Y (TTM)-20.35%
Revenue growth 3Y-11.71%
Revenue growth 5Y-4.09%
Sales Q2Q%-15.84%

3.2 Future

CSTE is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.51% yearly.
Based on estimates for the next years, CSTE will show a decrease in Revenue. The Revenue will decrease by -0.38% on average per year.
EPS Next Y-0.81%
EPS Next 2Y13.51%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-6.9%
Revenue Next 2Y-0.38%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
CSTE Yearly Revenue VS EstimatesCSTE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 200M 400M 600M
CSTE Yearly EPS VS EstimatesCSTE Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 1 -1 2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CSTE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CSTE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CSTE Price Earnings VS Forward Price EarningsCSTE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CSTE Per share dataCSTE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8 10

4.3 Compensation for Growth

A more expensive valuation may be justified as CSTE's earnings are expected to grow with 13.51% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.51%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

CSTE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CAESARSTONE LTD

NASDAQ:CSTE (6/4/2025, 10:32:19 AM)

1.75

+0.03 (+1.74%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryBuilding Products
Earnings (Last)05-07 2025-05-07/bmo
Earnings (Next)08-05 2025-08-05/bmo
Inst Owners37.16%
Inst Owner Change-1.15%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap60.48M
Analysts82.86
Price Target5.1 (191.43%)
Short Float %1.93%
Short Ratio2.97
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-19.02%
Min EPS beat(2)-49.19%
Max EPS beat(2)11.15%
EPS beat(4)2
Avg EPS beat(4)-17.78%
Min EPS beat(4)-49.19%
Max EPS beat(4)11.15%
EPS beat(8)3
Avg EPS beat(8)-168.56%
EPS beat(12)3
Avg EPS beat(12)-232.83%
EPS beat(16)6
Avg EPS beat(16)-163.56%
Revenue beat(2)1
Avg Revenue beat(2)-1.43%
Min Revenue beat(2)-3.48%
Max Revenue beat(2)0.62%
Revenue beat(4)1
Avg Revenue beat(4)-5.2%
Min Revenue beat(4)-11.77%
Max Revenue beat(4)0.62%
Revenue beat(8)2
Avg Revenue beat(8)-6.26%
Revenue beat(12)2
Avg Revenue beat(12)-5.9%
Revenue beat(16)4
Avg Revenue beat(16)-3.52%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-5.88%
EPS NQ rev (3m)-80%
EPS NY rev (1m)-13.33%
EPS NY rev (3m)-70%
Revenue NQ rev (1m)-2.64%
Revenue NQ rev (3m)-7.52%
Revenue NY rev (1m)-3.64%
Revenue NY rev (3m)-9.3%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.14
P/FCF N/A
P/OCF 7.52
P/B 0.23
P/tB 0.23
EV/EBITDA N/A
EPS(TTM)-1.02
EYN/A
EPS(NY)-0.61
Fwd EYN/A
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)0.23
OCFY13.3%
SpS12.28
BVpS7.66
TBVpS7.66
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -8.68%
ROE -17.69%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 20.93%
FCFM N/A
ROA(3y)-11.12%
ROA(5y)-6.06%
ROE(3y)-20.4%
ROE(5y)-11.19%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.44%
GM growth 5Y-4.33%
F-Score5
Asset Turnover0.79
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 57.35%
Cap/Sales 2.19%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.22
Quick Ratio 1.46
Altman-Z 1.48
F-Score5
WACC8.78%
ROIC/WACCN/A
Cap/Depr(3y)49.02%
Cap/Depr(5y)60.64%
Cap/Sales(3y)2.3%
Cap/Sales(5y)3.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)21.54%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-123.08%
EPS Next Y-0.81%
EPS Next 2Y13.51%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-20.35%
Revenue growth 3Y-11.71%
Revenue growth 5Y-4.09%
Sales Q2Q%-15.84%
Revenue Next Year-6.9%
Revenue Next 2Y-0.38%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y5.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year37.97%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y82.67%
FCF growth 3YN/A
FCF growth 5Y-18.43%
OCF growth 1Y1.81%
OCF growth 3Y15.48%
OCF growth 5Y-17.42%